DOCT — Beyond Medical Technologies Income Statement
0.000.00%
Last trade - 00:00- CA$8.08m
- CA$8.11m
Annual income statement for Beyond Medical Technologies, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.209 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | — | 0.025 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5.78 | 6.52 | 1.47 | 0.839 | 0.548 |
| Operating Profit | -5.78 | -6.32 | -1.47 | -0.839 | -0.548 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.37 | -6.52 | -1.87 | -0.835 | -0.552 |
| Net Income After Taxes | -5.37 | -6.52 | -1.87 | -0.835 | -0.552 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -5.37 | -6.52 | -2.91 | -1.4 | -0.596 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.37 | -6.52 | -2.91 | -1.4 | -0.596 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.606 | -0.479 | -0.248 | -0.106 | -0.07 |